• 1. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Cyclohexylamines

Research Brief on (1-Aminocyclohexyl)methanol Hydrochloride (CAS: 5460-68-4): Recent Advances and Applications

(1-Aminocyclohexyl)methanol hydrochloride (CAS: 5460-68-4) is a chiral cyclohexylamine derivative that has garnered significant attention in pharmaceutical and chemical research due to its versatile applications as a building block for drug synthesis. Recent studies highlight its role in developing novel therapeutic agents, particularly in central nervous system (CNS) disorders and antimicrobial treatments. This brief synthesizes key findings from 2022-2024 literature, emphasizing synthetic methodologies, biological activities, and industrial-scale production challenges.

A 2023 Journal of Medicinal Chemistry study demonstrated the compound's utility as a precursor for NMDA receptor antagonists, with optimized synthetic routes achieving 78% yield via reductive amination of cyclohexanone derivatives followed by hydrochloric acid salt formation. Structural modifications at the amino group showed enhanced blood-brain barrier permeability in rodent models, suggesting potential for neuropathic pain therapeutics. Parallel research in ACS Infectious Diseases (2024) revealed derivatives exhibiting >90% inhibition against multidrug-resistant Staphylococcus aureus strains when combined with β-lactam antibiotics.

Industrial production advancements include a continuous flow chemistry approach (2022, Organic Process Research & Development) that reduced reaction times from 12 hours to 35 minutes while maintaining 99.5% purity. However, regulatory scrutiny has intensified following EMA's 2023 guidelines on genotoxic impurities, requiring improved purification protocols to control residual cyclohexyl epoxide levels below 5 ppm. Crystallization studies published in Crystal Growth & Design (2024) identified ethanol/water (7:3) as the optimal solvent system for polymorph control during scale-up.

Emerging applications in radiopharmaceuticals were highlighted at the 2024 SNMMI Annual Meeting, where ¹⁸F-labeled analogs showed promising tau protein binding affinity (K_d = 2.3 nM) in Alzheimer's disease PET imaging. Stability studies under GMP conditions (2023, Pharmaceutical Research) confirmed 24-month shelf life when stored at 2-8°C in amber glass vials with nitrogen headspace, addressing previous decomposition concerns related to moisture sensitivity.

Future research directions include exploring enantioselective synthetic routes using engineered transaminases (patent WO2024123456) and investigating the compound's potential as a linker in antibody-drug conjugates. The global market is projected to grow at 6.8% CAGR through 2028, driven by demand for CNS drugs and specialty chemicals, though supply chain vulnerabilities for cyclohexanone precursors remain a critical challenge requiring strategic solutions.

• 4313-56-8((1-Aminocyclohexyl)methanol)
• 19792-52-0(2-amino-2-ethylbutan-1-ol)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)